Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD regimen in newly diagnosed transplant-eligible multiple myeloma
2011-001499-20Phase 2Completed
- Sponsor
- Meletios-Athanasios Dimopoulos
- Start
- Sep 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide, doxorubicin and dexamethasone in multiple myeloma (MM), sponsored by Meletios-Athanasios Dimopoulos. Primary endpoint: Response to RAD regimen. Started Sep 2014; status: completed.
02
Drugs
lenalidomidedoxorubicindexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2011-001499-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001499-20.